CO7180198A2 - Ariletinilo pirimidinas - Google Patents
Ariletinilo pirimidinasInfo
- Publication number
- CO7180198A2 CO7180198A2 CO15013232A CO15013232A CO7180198A2 CO 7180198 A2 CO7180198 A2 CO 7180198A2 CO 15013232 A CO15013232 A CO 15013232A CO 15013232 A CO15013232 A CO 15013232A CO 7180198 A2 CO7180198 A2 CO 7180198A2
- Authority
- CO
- Colombia
- Prior art keywords
- res
- formula
- mglur5
- autism
- schizophrenia
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invención se refiere a derivados de etinilo de la fórmula I: La presente invención se refiere a derivados de etinilo de la fórmula I: en la que: Res hidrógeno o halógeno; 1 Res alquilo Co -(CH)n-O-CH; 2 1-3 2 3 n es el número 2 ó 3; m es el número 1 ó 2; o a una sal de adición de ácido farmacéuticamente aceptable, a una mezcla racémica, o a su enantiómero correspondiente y/o isómero óptico y/o estereoisómero de los mismos. Se ha encontrado que los compuestos de la fórmula general I son moduladores alostéricos del receptor de glutamato metabotrópico del subtipo 5 (mGluR5) con propiedades mejoradas para el tratamiento de la esquizofrenia, las enfermedades cognitivas, el síndrome de la X frágil o el autismo. en la que: Res hidrógeno o halógeno; 1 Res alquilo Co -(CH)n-O-CH; 2 1-3 2 3 n es el número 2 ó 3; m es el número 1 ó 2; o a una sal de adición de ácido farmacéuticamente aceptable, a una mezcla racémica, o a su enantiómero correspondiente y/o isómero óptico y/o estereoisómero de los mismos. Se ha encontrado que los compuestos de la fórmula general I son moduladores alostéricos del receptor de glutamato metabotrópico del subtipo 5 (mGluR5) con propiedades mejoradas para el tratamiento de la esquizofrenia, las enfermedades cognitivas, el síndrome de la X frágil o el autismo.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12180209 | 2012-08-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO7180198A2 true CO7180198A2 (es) | 2015-02-09 |
Family
ID=46851291
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO15013232A CO7180198A2 (es) | 2012-08-13 | 2015-01-23 | Ariletinilo pirimidinas |
Country Status (36)
Country | Link |
---|---|
US (1) | US9199971B2 (es) |
EP (1) | EP2882742B1 (es) |
JP (1) | JP5974179B2 (es) |
KR (1) | KR101747005B1 (es) |
CN (1) | CN104540815B (es) |
AR (1) | AR092097A1 (es) |
AU (1) | AU2013304212B2 (es) |
BR (1) | BR112015002921A2 (es) |
CA (1) | CA2880257C (es) |
CL (1) | CL2015000290A1 (es) |
CO (1) | CO7180198A2 (es) |
CR (1) | CR20150028A (es) |
CY (1) | CY1118595T1 (es) |
DK (1) | DK2882742T3 (es) |
EA (1) | EA025165B1 (es) |
ES (1) | ES2601511T3 (es) |
HK (1) | HK1207378A1 (es) |
HR (1) | HRP20161692T1 (es) |
HU (1) | HUE030237T2 (es) |
IL (1) | IL237015A (es) |
LT (1) | LT2882742T (es) |
MA (1) | MA37895B1 (es) |
MX (1) | MX358011B (es) |
MY (1) | MY170255A (es) |
NZ (1) | NZ704858A (es) |
PE (1) | PE20150685A1 (es) |
PH (1) | PH12015500261B1 (es) |
PL (1) | PL2882742T3 (es) |
PT (1) | PT2882742T (es) |
RS (1) | RS55397B1 (es) |
SG (1) | SG11201501055SA (es) |
SI (1) | SI2882742T1 (es) |
TW (1) | TWI501958B (es) |
UA (1) | UA113223C2 (es) |
WO (1) | WO2014026880A1 (es) |
ZA (1) | ZA201500582B (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY174339A (en) | 2012-08-13 | 2020-04-09 | Novartis Ag | 1,4-disubstituted pyridazine analogs and methods for treating smn-deficiency-related conditions |
NZ703537A (en) * | 2012-10-18 | 2018-06-29 | Hoffmann La Roche | Ethynyl derivatives |
PT3303316T (pt) * | 2015-06-03 | 2020-04-27 | Hoffmann La Roche | Derivados de etinilo |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0325956D0 (en) | 2003-11-06 | 2003-12-10 | Addex Pharmaceuticals Sa | Novel compounds |
RS50603B (sr) * | 2004-06-01 | 2010-05-07 | F. Hoffmann-La Roche Ag. | Piridin-4-il-etinil-imidazoli i pirazoli kao antagonisti mglu5 receptora |
WO2006048771A1 (en) | 2004-11-04 | 2006-05-11 | Addex Pharmaceuticals Sa | Novel tetrazole derivatives as positive allosteric modulators of metabotropic glutamate receptors |
GB0503646D0 (en) * | 2005-02-22 | 2005-03-30 | Novartis Ag | Organic compounds |
GB0510139D0 (en) | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B1 |
TW200811157A (en) * | 2006-05-05 | 2008-03-01 | Astrazeneca Ab | mGluR5 modulators I |
WO2008151184A1 (en) * | 2007-06-03 | 2008-12-11 | Vanderbilt University | Benzamide mglur5 positive allosteric modulators and methods of making and using same |
KR20100089091A (ko) * | 2007-10-26 | 2010-08-11 | 아스트라제네카 아베 | Mglur5의 조절제로서의 아미노 1,2,4-트리아졸 유도체 |
US8334287B2 (en) * | 2009-07-17 | 2012-12-18 | Hoffmann-La Roche Inc. | Imidazoles |
US8389536B2 (en) * | 2009-10-27 | 2013-03-05 | Hoffmann-La Roche Inc. | Positive allosteric modulators (PAM) |
US8420661B2 (en) * | 2010-04-13 | 2013-04-16 | Hoffmann-La Roche Inc. | Arylethynyl derivatives |
CN103097391B (zh) * | 2010-07-09 | 2015-04-08 | 雷科尔达蒂爱尔兰有限公司 | 作为mGlu5拮抗剂的新型螺环杂环化合物 |
US8642626B2 (en) * | 2010-07-29 | 2014-02-04 | Taisho Pharmaceutical Co., Ltd. | Ethinyl-pyrazole derivative |
MY165141A (en) * | 2011-04-26 | 2018-02-28 | Hoffmann La Roche | Pyrazolidin-3-one derivatives |
US20130123254A1 (en) * | 2011-09-30 | 2013-05-16 | Barbara Biemans | Pharmaceutically acceptable mglur5 positive allosteric modulators and their methods of identification |
UA110995C2 (uk) * | 2011-10-07 | 2016-03-10 | Ф. Хоффманн-Ля Рош Аг | Етинільні похідні як модулятори метаботропного глутаматного рецептора |
UA110862C2 (uk) * | 2011-10-07 | 2016-02-25 | Ф. Хоффманн-Ля Рош Аг | Похідні етинілу як алостеричні модулятори метаботропного рецептора глутамату mglur 5 |
PL2875000T3 (pl) * | 2012-07-17 | 2017-03-31 | F.Hoffmann-La Roche Ag | Pochodne aryloetynylowe |
ES2594031T3 (es) * | 2012-09-27 | 2016-12-15 | F. Hoffmann-La Roche Ag | Derivados de ariletinilo |
-
2013
- 2013-06-08 UA UAA201501613A patent/UA113223C2/uk unknown
- 2013-08-06 EP EP13747827.7A patent/EP2882742B1/en active Active
- 2013-08-06 LT LTEP13747827.7T patent/LT2882742T/lt unknown
- 2013-08-06 CA CA2880257A patent/CA2880257C/en not_active Expired - Fee Related
- 2013-08-06 MY MYPI2015000358A patent/MY170255A/en unknown
- 2013-08-06 MA MA37895A patent/MA37895B1/fr unknown
- 2013-08-06 PL PL13747827T patent/PL2882742T3/pl unknown
- 2013-08-06 DK DK13747827.7T patent/DK2882742T3/en active
- 2013-08-06 MX MX2015001599A patent/MX358011B/es active IP Right Grant
- 2013-08-06 WO PCT/EP2013/066443 patent/WO2014026880A1/en active Application Filing
- 2013-08-06 SI SI201330420A patent/SI2882742T1/sl unknown
- 2013-08-06 KR KR1020157006196A patent/KR101747005B1/ko active IP Right Grant
- 2013-08-06 PT PT137478277T patent/PT2882742T/pt unknown
- 2013-08-06 ES ES13747827.7T patent/ES2601511T3/es active Active
- 2013-08-06 CN CN201380042690.0A patent/CN104540815B/zh active Active
- 2013-08-06 RS RS20161001A patent/RS55397B1/sr unknown
- 2013-08-06 EA EA201590252A patent/EA025165B1/ru not_active IP Right Cessation
- 2013-08-06 HU HUE13747827A patent/HUE030237T2/en unknown
- 2013-08-06 SG SG11201501055SA patent/SG11201501055SA/en unknown
- 2013-08-06 NZ NZ704858A patent/NZ704858A/en not_active IP Right Cessation
- 2013-08-06 AU AU2013304212A patent/AU2013304212B2/en not_active Ceased
- 2013-08-06 PE PE2015000196A patent/PE20150685A1/es active IP Right Grant
- 2013-08-06 JP JP2015526930A patent/JP5974179B2/ja active Active
- 2013-08-06 BR BR112015002921A patent/BR112015002921A2/pt not_active Application Discontinuation
- 2013-08-09 TW TW102128724A patent/TWI501958B/zh not_active IP Right Cessation
- 2013-08-12 AR ARP130102851A patent/AR092097A1/es not_active Application Discontinuation
-
2015
- 2015-01-22 CR CR20150028A patent/CR20150028A/es unknown
- 2015-01-23 CO CO15013232A patent/CO7180198A2/es unknown
- 2015-01-26 ZA ZA2015/00582A patent/ZA201500582B/en unknown
- 2015-01-29 IL IL237015A patent/IL237015A/en active IP Right Grant
- 2015-02-06 PH PH12015500261A patent/PH12015500261B1/en unknown
- 2015-02-06 CL CL2015000290A patent/CL2015000290A1/es unknown
- 2015-02-13 US US14/622,232 patent/US9199971B2/en active Active
- 2015-08-19 HK HK15108051.2A patent/HK1207378A1/xx unknown
-
2016
- 2016-12-12 HR HRP20161692TT patent/HRP20161692T1/hr unknown
- 2016-12-16 CY CY20161101305T patent/CY1118595T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2017011174A2 (es) | Derivados de etileno como moduladores metabotropicos de receptores de glutamato | |
CR20160212A (es) | Composiciones y métodos para modular los receptores x farnesoides | |
DOP2012000151A (es) | Nuevos compuestos triciclicos | |
ECSP15012804A (es) | Alcoxipirazoles como activadores de guanilato ciclasa soluble | |
NI201100016A (es) | Formulaciones farmacéuticas que contienen ligandos de receptores de dopamina. | |
EA201501122A1 (ru) | Новые агонисты соматостатиновых рецепторов подтипа 4 (sstr4) | |
AR078756A1 (es) | Moduladores alostericos positivos (map) | |
AR093042A1 (es) | Derivados de etinilo | |
AR086036A1 (es) | DERIVADOS DE ETINILO COMO MODULADORES ALOSTERICOS POSITIVOS DE (mGluR5) | |
EA201691046A1 (ru) | Производные этинилимидазолин-2,4-диона в качестве модуляторов метаботропного глутаматного рецептора 4 (mglur4) | |
CL2013003646A1 (es) | Compuestos derivados de trans-1-(3s.1r)-6-cloro-3-fenilindan-1-il)-1,2,2-trimetilpiperazina deuterados, con actividad en los receptores 5ht2, d1 y d2; proceso de preparacion; compuesto intermediario; composicion y combinacion farmaceutica; y su uso para el tratamiento de la psicosis, entre otros. | |
CO6801735A2 (es) | Derivados de pirazolidin-3-ona | |
CO7180198A2 (es) | Ariletinilo pirimidinas | |
AR096824A1 (es) | Derivados de etinilo | |
CO2018013824A2 (es) | Derivados de etinilo | |
AR093029A1 (es) | Derivados de etilino | |
AR091764A1 (es) | Derivados de ariletinilo | |
CR20150143A (es) | Derivados de etinilo como moduladores del receptor de actividad mglur5 | |
CO2017012260A2 (es) | Derivados de etinilo | |
CY1114699T1 (el) | Νεα νουκλεοσιδια 7-δεαζαπουρινης για θεραπευτικες χρησεις | |
CL2010000415A1 (es) | Compuestos derivados de fenil-etilen-octahidro-indol, antagonista mglur5; utiles en el tratamiento de enfermedades del snc (divisional de la solicitud cl 2764-02). | |
CU20130106A7 (es) | Moduladores del receptor de glucagón |